| 70.62 -3.71 (-4.99%) | 05-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 109.63 |
1-year : | 127.31 |
| Resists | First : | 93.86 |
Second : | 109 |
| Pivot price | 81.64 |
|||
| Supports | First : | 69.37 |
Second : | 57.72 |
| MAs | MA(5) : | 75.61 |
MA(20) : | 84.96 |
| MA(100) : | 64.23  |
MA(250) : | 48.77 |
|
| MACD | MACD : | -1.4 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 3.7 |
D(3) : | 4.7 |
| RSI | RSI(14): 33 |
|||
| 52-week | High : | 109 | Low : | 7.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NKTR ] has closed below the lower bollinger band by 7.7%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ NKTR ] is to continue within current trading range. Bollinger Bands are 3.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 74.29 - 75 | 75 - 75.44 |
| Low: | 67.91 - 68.82 | 68.82 - 69.36 |
| Close: | 69.58 - 71.06 | 71.06 - 71.95 |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Sat, 16 May 2026
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares - The Motley Fool
Sat, 16 May 2026
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares - The Globe and Mail
Fri, 15 May 2026
BVF Group (NKTR) reports up to 2.85M shares—9.8% aggregate holding - Stock Titan
Thu, 14 May 2026
NKTR Stock Price, Quote & Chart | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill
Wed, 13 May 2026
Assessing Nektar Therapeutics (NKTR) Valuation After Its Recent Share Price Recovery - simplywall.st
Tue, 12 May 2026
Assessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price Momentum - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 34 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 56.9 (%) |
| Shares Short | 3,630 (K) |
| Shares Short P.Month | 3,670 (K) |
| EPS | -9.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.4 |
| Profit Margin | -297.1 % |
| Operating Margin | -87.6 % |
| Return on Assets (ttm) | -28 % |
| Return on Equity (ttm) | -218 % |
| Qtrly Rev. Growth | -25.3 % |
| Gross Profit (p.s.) | 1.63 |
| Sales Per Share | 1.63 |
| EBITDA (p.s.) | -3.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -209 (M) |
| Levered Free Cash Flow | -108 (M) |
| PE Ratio | -7.26 |
| PEG Ratio | 0.3 |
| Price to Book value | 16.01 |
| Price to Sales | 43.14 |
| Price to Cash Flow | -11.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|